Biotechnology
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a$50 million series A financing, to accelerate its innovative pipeline developme...
2021-03-01 19:50
4430
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers
SHANGHAI, March 1, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited, a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan designation for CT041, CARsgen's first-in-class Claudin 18.2 (CLDN18.2) targeted CAR-T product candidate ...
2021-03-01 19:00
3411
Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
- Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus che...
2021-03-01 18:48
2369
Avalon SteriTech and SoftBank Robotics Group Launch New Joint Venture to Develop and Promote Innovative Public Healthcare and Hygiene Solutions
HONG KONG, March 1, 2021 /PRNewswire/ -- Avalon SteriTech Limited ("Avalon") and SoftBank Robotics Group ("SBRG") today announced a joint venture focusing on the development of innovative products and technologies that strive to empower and benefit public health and well-being. The joint venture ...
2021-03-01 13:00
1676
Sciwind's Investigational New Drug Approved for NASH Trial
HANGZHOU, China, March 1, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., (Sciwind), a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatit...
2021-03-01 09:00
2296
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-03-01 08:23
5638
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
5648
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, March 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
2306
Alterity to present at the 7th International Congress of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...
2021-02-26 20:45
6013
Debiopharm And Genome & Company Join Forces To Create New Highly Specific Therapies For Cancer Patients
Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates LAUSANNE, Switzerland and SEONGNAM-SI GYEONGGI-DO, South Korea, Feb. 26, 2021 /PRNewswire/ -- Genome & Company (CEO:Jisoo Pae, Hanso...
2021-02-26 19:14
3180
Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform
BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen's antibody discove...
2021-02-25 23:45
1552
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients
SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...
2021-02-25 07:00
1956
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021
HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...
2021-02-25 05:16
9776
Zymergen Appoints Global Finance Expert Enakshi Singh as Chief Financial Officer
EMERYVILLE, Calif., Feb. 24, 2021 /PRNewswire/ -- Biofacturing leader Zymergen today announced it has promotedEnakshi (Ena) Singh to Chief Financial Officer. Singh has helped Zymergen close more than$1B in equity financing and $100M in debt since joining Zymergen as vice president of finance in 2...
2021-02-24 22:30
4532
VLP BioTech, Inc. Announces an Immunotherapy Designed for the Treatment of Chronic HBV/HDV Infections
- VLP BioTech Has Developed a Vaccine-Based Viral-Entry-Inhibitor for the Treatment of Chronic HBV/HDV. - The Vaccine-Based Treatment Has Significant Advantages Compared to a Peptide-Based, Entry-Inhibitor (Hepcludex). SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- VLP BioTech, Inc., a private, pre...
2021-02-24 22:00
2720
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
- Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions - QIAGEN's bioinformatic expertise raises predictive biomarker power in INOVIO's patient selection - First-in-class next genera...
2021-02-24 14:45
5788
Alternative meat startup Next Meats Co., Ltd and microalgae biotech company euglena Co., launch "NEXT Euglena Yakiniku EX" containing microalgae
TOKYO, Feb. 12, 2021 /PRNewswire/ -- Next Meats Co., LTD, the controlling shareholder of Next Meats Holdings, Inc. ("OTC: NXMH") announced that they had signed a joint product development agreement witheuglena Co., a biotech company also fromJapan which specializes in cultivating Euglena and Chlo...
2021-02-24 12:45
5356
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
SHANGHAI and HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and onco...
2021-02-24 08:00
2490
US Court Grants MGI's Motion to Amend in Suit Against Illumina
SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- A judge in the U.S. District Court for the Northern District ofCalifornia has granted MGI's motion for leave to amend to add a new inequitable conduct defense of patent infringement lawsuit that Illumina filed against MGI inFebruary 2020 (Case No. 20-c...
2021-02-24 04:00
3393
GBB Completes USD$3.8M Convertible Note Financing Led by Alibaba Hong Kong Entrepreneurs Fund
HONG KONG, Feb. 23, 2021 /PRNewswire/ -- Great Bay Bio Holdings Limited (hereinafter referred to as "GBB") today announced it has completed aUSD$3.8M Convertible Note Financing. Alibaba Hong Kong Entrepreneurs Fund (hereinafter referred to as "AEF") led the investment round with participation fro...
2021-02-23 23:00
1881
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00
Animated Life in Yunnan
[Picked up by 275 media titles]
2024-04-18 14:00
Most Read
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
6410
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
6342
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
2024-04-12 20:08
4528
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3796